Science News
from research organizations

microRNAs help to predict disease progression in brain tumors

Date:
June 14, 2016
Source:
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health
Summary:
A new method of predicting disease progression in gliobastoma patients who have undergone standard treatment has been developed by scientists. Their findings show that four miRNAs may hold the vital clue.
Share:
FULL STORY

Irradiation planning of a glioblastoma.
Credit: Klinikum der Universität München

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich (LMU) have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment. Their findings, published in the journal Oncotarget, show that four miRNAs may hold the vital clue. An application for the corresponding patent has already been filed.

Roughly one fifth of all brain tumors diagnosed by doctors are gliobastomas. This aggressive and most common type of brain tumor continues to present doctors with huge challenges. However, molecular markers could help them to make the right treatment decision. A team of researchers led by Dr. Kristian Unger, Deputy Head of the Radiation Cytogenetics Research Unit (headed by Prof. Dr. Horst Zitzelsberger) at the Helmholtz Zentrum München, and Prof. Dr. Claus Belka, Director of the Clinic and Policlinic for Radiotherapy and Radiation Oncology at the University of Munich's Grosshadern Hospital (member of the DKTK cancer research consortium), has now succeeded in identifying specific miRNAs that could serve as biomarkers for disease progression.

miRNAs indicate a poor prognosis

In collaboration with the Institute of Neurology (Edinger Institute) at the University Hospital Frankfurt, researchers examined the composition of miRNAs in samples from 36 patients from whom tumor material had been removed during treatment, and whose subsequent course of treatment had been well documented. "We repeatedly detected four miRNAs in tumors that had a particularly poor prognosis," explains PD Dr. Karim-Maximilian Niyazi, senior physician at Grosshadern, and first author of the study. Based on their data, the scientists calculated a risk score to distinguish two patient groups who were undergoing standard treatment and whose life expectancy varied by about five months. In order to corroborate their findings, they used data obtained from a further 58 independent samples. Here, too, they found that the composition of the miRNAs altered, the worse the prospects of a successful treatment outcome were.

Patent already applied for

The scientists are confident that their observations will have more than mere theoretical implications. For this reason, they have already filed an application for the corresponding patent. "To date only few prognostic and predictive factors for glioblastoma have been identified," says research team leader Unger. "Our method could be used to identify candidates for alternative or intensified treatment options, as it is highly unlikely that patients with a high risk score would benefit from standard therapy." Since tumor tissue would generally be removed immediately, a corresponding analysis would be relatively easy to conduct and would not require any additional time or expense, the researchers note.

Whether the miRNAs have a malignant function in the cancer cells themselves or are merely an indirect marker remains to be clarified. In initial studies, however, the scientists have shown that miRNAs could possibly even play a role in various processes of tumor development.


Story Source:

Materials provided by Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. Note: Content may be edited for style and length.


Journal Reference:

  1. Michel Mittelbronn, Joachim Steinbach, Carsten Sticht, Franz Zehentmayr, Daniel Piehlmaier, Horst Zitzelsberger, Ute Ganswindt, Claus Rödel, Kirsten Lauber, Claus Belka, Kristian Unger. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget, 2014; DOI: 10.18632/oncotarget.9945

Cite This Page:

Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "microRNAs help to predict disease progression in brain tumors." ScienceDaily. ScienceDaily, 14 June 2016. <www.sciencedaily.com/releases/2016/06/160614084216.htm>.
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. (2016, June 14). microRNAs help to predict disease progression in brain tumors. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/06/160614084216.htm
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "microRNAs help to predict disease progression in brain tumors." ScienceDaily. www.sciencedaily.com/releases/2016/06/160614084216.htm (accessed May 23, 2017).

RELATED STORIES